Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 1307Carcinoma, Renal Cell 660Urinary Bladder Neoplasms 405Carcinoma, Non-Small-Cell Lung 333Neoplasms 301Carcinoma, Transitional Cell 263Breast Neoplasms 252Ovarian Neoplasms 248Melanoma 235Colorectal Neoplasms 227Neoplasm Metastasis 214Kidney Neoplasms 200Pancreatic Neoplasms 169Stomach Neoplasms 162Squamous Cell Carcinoma of Head and Neck 143Lung Neoplasms 140Uterine Cervical Neoplasms 123Non-Muscle Invasive Bladder Neoplasms 118Triple Negative Breast Neoplasms 112Head and Neck Neoplasms 111Endometrial Neoplasms 109Esophageal Neoplasms 107Carcinoma, Hepatocellular 97Small Cell Lung Carcinoma 80Sarcoma 75Colonic Neoplasms 55Urologic Neoplasms 53Prostatic Neoplasms, Castration-Resistant 47Liver Neoplasms 47Cholangiocarcinoma 43

Interventions

radium Ra 223 dichloride 1Pluvicto 1Lutetium-177 1Lutetium 1BAY 2315497 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Castration Resistant Prostate Cancer (mCRPC) × Genitourinary × Clear all
NCT06894511 2026-05-01

PSMAndARPI

Novartis

Phase 2 Active not recruiting
7 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03724747 2024-11-08

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Bayer

Phase 1 Completed
63 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT04516161 2022-03-31

EPIX

Bayer

Completed
1,180 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡